Day 1: New Tech WS has finished! Feeling inspired, excited & informed following great presentations & discussions on replacement & non-replacement therapies and gene & cell therapies. Very pleased that we can finally discuss innovations for extremely rare bleeding disorders!!
@ProfMakris Maybe we should see if one of the NHS pharmacies is keen to take this on as a revenue source. I know Royal london hospital used to have a manufacturing unit, which is now closed because of staff shortages and lack of funding.
“Gene therapy represents a natural progression in treatment... the future aim is to provide the patient with the genetic code to produce endogenous factor...” @bcndoc @RoyalLondonHosp Get the latest on #haemophilia and gene therapy in our April Bulletin. https://t.co/4FuBTLber4
@pat97404965@DrAmirKhanGP The difference lies in that if you replied London people would stop there and not continue asking but where are you really from?
A lot of medicine is doing trials in white men and then treating the rest of the population based on what we’ve learned.
And we wonder why it doesn’t work.
Health equity MUST begin in trials. #ISTH2022
@acweyand@VJHemOnc@GuyYoungMD Completely agree, as a previous transplanter and now haemophilia treater, I wouldn’t want to expose my patients to this level of toxicity
We had a lovely interview this morning with Priyanka Raheja (@bcndoc) at #ISTH2022 on managing patients with hemophilia treated with gene therapy.
Stay tuned for our interviews on https://t.co/O9p0vDBrzw!
@isth#RareDiseases#Hemophilia#HemOnc